Shire PLC (SHPG) Stock Rating Reaffirmed by Cantor Fitzgerald
Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research note issued on Friday. They currently have a $222.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 56.15% from the stock’s current price.
SHPG has been the topic of several other research reports. BidaskClub downgraded Shire PLC from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. Barclays PLC downgraded Shire PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, August 11th. Evercore ISI assumed coverage on Shire PLC in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $196.00 price objective for the company. Royal Bank Of Canada reissued a “buy” rating and issued a $213.00 price objective on shares of Shire PLC in a research report on Monday, October 2nd. Finally, Piper Jaffray Companies set a $159.00 price objective on Shire PLC and gave the company a “hold” rating in a research report on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $219.33.
Shire PLC (SHPG) traded up 2.84% during mid-day trading on Friday, hitting $142.17. 2,091,441 shares of the stock were exchanged. Shire PLC has a one year low of $137.80 and a one year high of $192.64. The company has a market cap of $42.35 billion, a P/E ratio of 63.61 and a beta of 1.63. The company has a 50-day moving average price of $152.36 and a 200-day moving average price of $163.12.
Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, beating the consensus estimate of $3.64 by $0.17. Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. The company had revenue of $3.70 billion for the quarter, compared to the consensus estimate of $3.72 billion. During the same quarter last year, the company posted $3.17 earnings per share. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year. Analysts forecast that Shire PLC will post $14.92 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/28/shire-plc-shpg-stock-rating-reaffirmed-by-cantor-fitzgerald.html.
Several hedge funds and other institutional investors have recently modified their holdings of the business. Inspirion Wealth Advisors LLC lifted its holdings in shares of Shire PLC by 0.4% during the second quarter. Inspirion Wealth Advisors LLC now owns 1,944 shares of the biopharmaceutical company’s stock valued at $321,000 after acquiring an additional 8 shares during the period. Synovus Financial Corp lifted its holdings in shares of Shire PLC by 0.4% during the second quarter. Synovus Financial Corp now owns 2,780 shares of the biopharmaceutical company’s stock valued at $458,000 after acquiring an additional 11 shares during the period. Baldwin Investment Management LLC lifted its holdings in shares of Shire PLC by 1.4% during the second quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 23 shares during the period. Hartford Financial Management Inc. lifted its holdings in shares of Shire PLC by 5.4% during the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 32 shares during the period. Finally, American International Group Inc. lifted its holdings in shares of Shire PLC by 1.2% during the first quarter. American International Group Inc. now owns 4,607 shares of the biopharmaceutical company’s stock valued at $803,000 after acquiring an additional 54 shares during the period. 19.23% of the stock is owned by institutional investors.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.